<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227474</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000441167</org_study_id>
    <secondary_id>S0348</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00227474</nct_id>
  </id_info>
  <brief_title>S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission</brief_title>
  <official_title>S0348: A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective&#xD;
      immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune&#xD;
      response and prevent or delay the recurrence of cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients&#xD;
      with stage IIIB or stage IV breast cancer in remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of conducting a live viral vaccine trial using adjuvant&#xD;
           recombinant modified vaccinia Ankara-5T4 vaccine (TroVax®) in patients with stage&#xD;
           IIIB-IV breast cancer in remission.&#xD;
&#xD;
        -  Determine the progression-free survival of patients treated with this vaccine.&#xD;
&#xD;
        -  Determine the 5T4-specific T-cell immune response in patients treated with this vaccine.&#xD;
&#xD;
        -  Determine the toxicity of this vaccine in these patients.&#xD;
&#xD;
        -  Determine the level of 5T4-specific antibody response in patients treated with this&#xD;
           vaccine.&#xD;
&#xD;
        -  Correlate, preliminarily, immune response with 3- and 12-month progression-free survival&#xD;
           of patients treated with this vaccine.&#xD;
&#xD;
        -  Correlate tumor 5T4 expression with overall survival and progression-free survival of&#xD;
           patients treated with this vaccine.&#xD;
&#xD;
        -  Correlate tumor infiltrating lymphocyte and CD1a-positive dendritic cell density with&#xD;
           development of 5T4-specific T-cell immunity in patients treated with this vaccine.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive recombinant modified vaccinia Ankara-5T4 vaccine (TroVax®) intramuscularly&#xD;
      once a month in months 1-3. Patients then receive booster vaccinations once in months 6, 9,&#xD;
      and 12. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    SWOG has decided to not pursue this trial&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant modified vaccinia Ankara-5T4 vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>recombinant viral vaccine therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Stage IIIB-IV disease&#xD;
&#xD;
                    -  Patients with stage IV disease must have metastasis to the bone only AND&#xD;
                       documentation of negative or improved bone scan showing evidence of&#xD;
                       recalcification by plain film x-ray OR MRI showing normalization of marrow&#xD;
                       signal&#xD;
&#xD;
          -  In remission (no evidence of disease)&#xD;
&#xD;
               -  Must have completed appropriate treatment (e.g., radiotherapy and chemotherapy)&#xD;
                  for primary disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No known history of hepatitis B or C&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No known history of immune-deficiency disorder&#xD;
&#xD;
          -  No history of allergic reaction to prior vaccinia vaccinations&#xD;
&#xD;
          -  No autoimmune disease requiring concurrent treatment&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Concurrent trastuzumab (Herceptin®) allowed provided it is not part of treatment on&#xD;
             another clinical trial&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 28 days since prior steroid therapy&#xD;
&#xD;
          -  Concurrent hormonal therapy allowed provided it is not part of treatment on another&#xD;
             clinical trial&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 28 days since prior and no concurrent treatment on another clinical trial&#xD;
&#xD;
               -  Patients enrolled in a SWOG phase III metastatic trial (e.g.,SWOG-S0226 or&#xD;
                  SWOG-S0347) who have achieved complete remission but not yet progressed are not&#xD;
                  eligible&#xD;
&#xD;
               -  Patients enrolled in a SWOG phase II metastatic trial or phase II/III adjuvant or&#xD;
                  neoadjuvant trial (e.g., SWOG-S0012, SWOG-S0215, SWOG-S0221, SWOG-S0338, or&#xD;
                  SWOG-S0430) who have achieved complete remission/no evidence of disease status&#xD;
                  and are no longer receiving study treatment are eligible&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed provided it is not part of treatment on another&#xD;
             clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lupe G. Salazar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tumor Vaccine Group at the University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary (Nora) L. Disis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

